GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8.
Under the deal, GSK will receive a $320 million cash payment. The drugmaker also will collect a 1% royalty on any future U.S. sales of influenza, COVID-19 and related combination mRNA vaccines developed by BioNTech and Pfizer.
CureVac announced Aug. 7 it had reached agreements with BioNTech and Pfizer to resolve pending U.S. patent litigation tied to mRNA technology, resulting in a total payment of $740 million between the two drugmakers.
GSK said the settlement does not affect its ongoing patent enforcement actions against BioNTech and Pfizer in the U.S. and Europe, according to the Journal.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
